Population-Based Screening for Trisomies and Atypical Chromosomal Abnormalities: Improving Efficacy using the Combined First Trimester Screening Algorithm as well as Individual Risk Parameters.


Journal

Fetal diagnosis and therapy
ISSN: 1421-9964
Titre abrégé: Fetal Diagn Ther
Pays: Switzerland
ID NLM: 9107463

Informations de publication

Date de publication:
2019
Historique:
received: 14 05 2018
accepted: 06 07 2018
pubmed: 11 9 2018
medline: 7 1 2020
entrez: 11 9 2018
Statut: ppublish

Résumé

To examine the performance of the combined First Trimester Screening (cFTS) algorithm when outliers of 4 risk parameters (maternal age, nuchal translucency (NT) thickness, PAPP-A and β-hCG) were included in the classification of "high-risk". A retrospective analysis of singleton pregnancies undergoing cFTS between 2008 and 2011 in Denmark. Abnormal karyotypes were classified as trisomy 21 (T21), trisomy 13 (T13) and trisomy 18 (T18), sex chromosome aberrations and atypical abnormal karyotypes. cFTS was completed in 193,638 pregnancies. In 10,205 (5.3%) cases, cytogenetic or molecular analysis was performed pre- or postnatally. An abnormal karyotype was seen in 1,122 (11.0%). The algorithm identified 87% of T21, 80% of T13, 75% of T18, 79% of sex chromosome aberrations and 35% of atypical abnormal karyotypes. Additional classification of a single risk parameter outlier (low PAPP-A or free β-hCG (< 0.2 MoMs), high β-hCG (≥5.0 MoMs), maternal age ≥45 years or NT ≥3.5 mm) as being at high-risk would have improved detection rates to 88, 80, 81, 81 and 37% respectively. The screen positive rate increased from 4.4 to 4.8%. Addition of outliers of the 4 parameters used in cFTS algorithm will lead to a statistically significant increase in detection rates for chromosomal abnormality.

Identifiants

pubmed: 30199859
pii: 000492152
doi: 10.1159/000492152
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

424-429

Informations de copyright

© 2018 S. Karger AG, Basel.

Auteurs

Ida Vogel (I)

Departments of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark, idavogel@rm.dk.
Center for Fetal Diagnostics, Aarhus University Hospital, Aarhus, Denmark, idavogel@rm.dk.
Institute of Biomedicine, Aarhus University, Aarhus, Denmark, idavogel@rm.dk.

Ann Tabor (A)

Fetal Medicine Unit, Department of Obstetrics and Gynecology, Copenhagen University Hospital, Copenhagen, Denmark.

Charlotte Ekelund (C)

Fetal Medicine Unit, Department of Obstetrics and Gynecology, Copenhagen University Hospital, Copenhagen, Denmark.

Stina Lou (S)

Center for Fetal Diagnostics, Aarhus University Hospital, Aarhus, Denmark.
DEFACTUM, Central Denmark Region, Aarhus, Denmark.

Jon Hyett (J)

Discipline of Obstetrics, Gynaecology and Neonatology, University of Sydney, Sydney, New South Wales, Australia.

Olav Bjørn Petersen (OB)

Center for Fetal Diagnostics, Aarhus University Hospital, Aarhus, Denmark.
Department of Obstetrics and Gynecology, Aarhus University Hospital, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH